Abstract | BACKGROUND: METHODS: FINDINGS: 63 (19%) of 339 patients in the vaccine group and 57 (16%) of 352 patients in the placebo group developed a new pneumonia, corresponding to a relative risk over time for the placebo group compared with the vaccine group of 0.83 (95% CI 0.58-1.12, p=0.31). Pneumococcal pneumonia was diagnosed in 16 (4.5%) patients in the placebo group and in 19 (5.6%) in the vaccine group, corresponding to a relative risk for the placebo group of 0.78 (95% CI 0.40-1.51, p=0.45). We found no difference in the death rate between the two study groups. INTERPRETATION:
|
Authors | A Ortqvist, J Hedlund, L A Burman, E Elbel, M Höfer, M Leinonen, I Lindblad, B Sundelöf, M Kalin |
Journal | Lancet (London, England)
(Lancet)
Vol. 351
Issue 9100
Pg. 399-403
(Feb 07 1998)
ISSN: 0140-6736 [Print] England |
PMID | 9482293
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bacterial Vaccines
- Pneumococcal Vaccines
|
Topics |
- Aged
- Aged, 80 and over
- Bacterial Vaccines
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Incidence
- Male
- Middle Aged
- Pneumococcal Vaccines
- Pneumonia
(epidemiology, prevention & control)
- Pneumonia, Pneumococcal
(epidemiology, prevention & control)
- Proportional Hazards Models
- Prospective Studies
- Recurrence
- Risk Factors
- Streptococcus pneumoniae
- Vaccination
|